November 12, 2022:

Cheryl L. Knott, PhD, is a Professor in the Department of Behavioral and Community Health, as well as Co-Leader of the Population Science Program and Associate Director of Community Outreach and Engagement at the University of Maryland Greenebaum Comprehensive Cancer Center. She is also Editor-in-Chief of the peer-reviewed journal, Translational Behavioral Medicine.

Dr. Knott’s interventional research examines implementation, adaptation, and sustainability of evidence-based cancer control interventions in community based settings, with a focus on cancer disparities impacting African Americans. She also studies organizational factors that influence outcomes across the implementations continuum. In a recent study, she evaluated implementation strategies to institutionalize evidence-based cancer education in African American church settings.

Her social epidemiology research examines multi-level factors (e.g., individual, interpersonal, neighborhood) that play a role in cancer control behavior in African Americans, with an emphasis on social justice and structural racism. Dr. Knott’s research program has generated more that $13 million in extramural support as Principal Investigator, from sources such as the NIH, CDC, and ACS. Ther program has resulted in more than 150 peer-reviewed publications, most including student co-authors.

Three interesting facts about Cheryl L. Knott, PhD:

  • I embrace lifelong learning and during the pandemic started playing music again after a long hiatus; I played clarinet in middle and high school.
  • I am a first-generation college student and an only child; my parents are Vietnam-era veterans and served in the US Air Force.
  • My husband and I recently welcomed a new puppy into our home. He’s a loveable little “disrupter.”

About the Big Ten Cancer Research Consortium: The Big Ten cancer centers have united to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team-research culture to drive science rapidly from ideas to treatment-changing paradigms. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org